Enanta Pharmaceuticals (ENTA) Receivables - Net (2016 - 2025)
Enanta Pharmaceuticals (ENTA) has disclosed Receivables - Net for 14 consecutive years, with $8.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 10.04% year-over-year to $8.5 million, compared with a TTM value of $8.5 million through Dec 2025, up 10.04%, and an annual FY2025 reading of $6.9 million, up 3.55% over the prior year.
- Receivables - Net was $8.5 million for Q4 2025 at Enanta Pharmaceuticals, up from $6.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $27.6 million in Q4 2021 and bottomed at $6.6 million in Q3 2024.
- Average Receivables - Net over 5 years is $14.4 million, with a median of $13.2 million recorded in 2023.
- The sharpest move saw Receivables - Net grew 15.93% in 2021, then crashed 63.81% in 2023.
- Year by year, Receivables - Net stood at $27.6 million in 2021, then decreased by 18.31% to $22.6 million in 2022, then plummeted by 63.81% to $8.2 million in 2023, then fell by 5.57% to $7.7 million in 2024, then increased by 10.04% to $8.5 million in 2025.
- Business Quant data shows Receivables - Net for ENTA at $8.5 million in Q4 2025, $6.9 million in Q3 2025, and $8.3 million in Q2 2025.